# Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Source: https://onco.cc/trials/nct04423211/  
OnCo record `nct04423211` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide, Degarelix, Fluciclovine F-18, Goserelin / leuprolide, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by ECOG-ACRIN Cancer Research Group, now recruiting.

## Summary

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging is a phase 3 interventional study registered as NCT04423211 by ECOG-ACRIN Cancer Research Group, with 804 participants planned, started 2020-10-08 and due to reach its primary completion in 2032-12-31. Interventions recorded: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy. Conditions recorded: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8.

Linked to the drug Fluciclovine F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04423211
- Phase: 3
- Setting: Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
- Sponsor: ECOG-ACRIN Cancer Research Group
- Enrolled: 804

## Sources

- ClinicalTrials.gov NCT04423211: https://clinicaltrials.gov/study/NCT04423211

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/), [Degarelix](https://onco.cc/drugs/degarelix/), [Fluciclovine F-18](https://onco.cc/drugs/fluciclovine-f18/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/), [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/), [Relugolix](https://onco.cc/drugs/relugolix/), [Triptorelin](https://onco.cc/drugs/triptorelin/)

---
JSON: https://onco.cc/api/v1/entities/nct04423211.json